Nasdaq
$67.82▼ 0.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.92BShares out 43.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 10.13After-hours26.10.14 06:02S-3ASROffering#●●●#●●●
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals has registered the resale of 2,908,692 shares of common stock issued to shareholders of Alkeus Pharmaceuticals as consideration for the acquisition completed on September 4, 2026. This filing facilitates the potential resale of these shares by the selling stockholders, and the company will not receive any proceeds from these sales.…more
$67.82-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 05:30S-3ASROffering
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals has registered the resale of up to 2,232,144 shares of its common stock, consisting of 2,098,519 shares issued in a private placement and 133,625 shares issuable upon the exercise of pre-funded warrants. This registration facilitates the potential resale of shares by selling stockholders and does not involve any new capital raising for the company. Selling stockholders may dispose of these shares from time to time at prevailing market prices or negotiated prices.…more
$67.82-0.47%vs prev closeView filingShare - 10.13After-hours26.10.14 05:008-K/AKey event
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, and this Form 8-K/A provides the required historical financial statements of Alkeus and pro forma financial information. Alkeus reported substantial doubt regarding its ability to continue as a going concern, and Tarsus has accounted for the acquisition as the initial consolidation of a variable interest entity (VIE).…more
$67.82-0.47%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13After-hours26.10.14 06:06Bullish#●●●
Tarsus Pharmaceuticals Files Prospectus for Resale of 2.91M Shares
Tarsus Pharmaceuticals has filed a prospectus with the SEC regarding the potential resale of up to 2.91 million shares by selling stockholders. This filing facilitates the secondary market sale of existing shares rather than a new capital raise.…more
$67.82-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Pre-market26.09.29 21:30
●●●●●●●● ●●●●● ●●●●●●
Tarsus Pharmaceuticals will present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting. The research highlights new insights into Demodex blepharitis, ocular rosacea, and real-world outcomes of its treatment, XDEMVY.…more
$67.82-0.47%vs prev close - 9.4Pre-market26.09.04 21:38
●●●●●●●● ●●●●● ●●●●●●
Tarsus Pharmaceuticals has finalized its acquisition of Alkeus Pharmaceuticals, gaining control of a late-stage oral treatment candidate for Stargardt disease. While the deal strengthens Tarsus's eye care portfolio, the key Phase 3 clinical data for the acquired asset is not expected until 2029.…more
$67.82-0.47%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report